HOOKIPA Pharma Reports First Quarter 2019 Financial Results and Recent Business Highlights NEW YORK and VIENNA, Austria, May 20, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers...

HOOKIPA Achieves Research Milestone in HBV Collaboration and License Agreement with Gilead NEW YORK and VIENNA, Austria, May 08, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers...

HOOKIPA Appoints David R. Kaufman to its Board of Directors NEW YORK and VIENNA, Austria, April 25, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers...

HOOKIPA Pharma Announces Pricing of Initial Public Offering NEW YORK, April 17, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its...